Market World Gastroesophageal Reflux Disease Therapeutics | Page 3

Competitive Insights
Competitive market, which is generics-driven is creating a pressure on the prices of drug with decreased retail
sales, which will stimulate stationary growth in future. Companies producing them range from high to medium
on the basis of competitive rivalry. Eisai Co., Ltd.; AstraZeneca PLC; GlaxoSmithKline PLC; Johnson & Johnson
and Takeda Pharmaceutical Co., Ltd.; are some of the top key players. In addition, Daewoong Pharmaceutical
Co., Ltd.; SRS Pharmaceuticals Pvt. Ltd.; SFJ Pharmaceuticals Group and Ironwood Pharmaceuticals, Inc. are
some emerging companies.
Among others, RaQualia Pharma, Inc. and Ironwood Pharmaceuticals, Inc. are focusing more on development
of new generic molecules, which involves novel and existing drug mechanisms as a part of the strategy to enter
into the competition. Many generic players are also trying to focus on these spaces in an attempt to capture a
larger share by the new version to replace the patent expired drugs.
Market Segment:
GERD Therapeutics Drug Type Outlook (Revenue, USD Million, 2014 - 2025)
• Antacids
• H2 Receptor Blockers
• Proton Pump Inhibitors (PPIs)
• Pro-kinetic agents
GERD Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)
• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• Asia Pacific
• Japan
• China
• India
• Latin America
• Brazil
• Middle East and Africa (MEA)
• South Africa